- cafead   Mar 21, 2024 at 06:42: PM
via Amid congressional scrutiny on U.S. inhaler prices, GSK is the latest pharma giant to commit to capping patients' monthly payments for its portfolio of asthma and chronic obstructive pulmonary disease (COPD) meds.
article source
article source